Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › T-cell prolymphocytic leukemia

T-cell prolymphocytic leukemia

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for T-cell prolymphocytic leukemia

6 trials tracked for T-cell prolymphocytic leukemia.

6Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 5 Phase 1 1
  1. Phase 2 Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Completed
  2. Phase 2 Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Completed
  3. Phase 2 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Completed
  4. Phase 2 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed
  5. Phase 2 Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Completed
  6. Phase 1 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Alemtuzumab-based therapy achieves 81.9% response rate in adult T-cell prolymphocytic leukemia
Oncology Meta-analysis
Alemtuzumab-based therapy achieves 81.9% response rate in adult T-cell prolymphocytic leukemia Alemtuzumab Therapy Shows High Response Rates for T-cell Leukemia
This meta-analysis of 200 patients with T-cell prolymphocytic leukemia (T-PLL) found an 81.9% overall response rate to alemtuzumab-based the…
Alemtuzumab-based therapy shows an 81.9% response rate for adults with T-cell prolymphocytic leukemia, with some patients surviving long-ter…
Sep 11, 2026